5.1 Investigational New Drug (IND) Applications (21 CFR Part 312)

Investigational New Drug (IND) Applications (21 CFR Part 312)

The Regulatory Basis and Exemption Purpose of the IND

The clinical development of a new pharmaceutical agent in the United States is a highly regulated, multi-stage process overseen by the Food and Drug Administration (FDA). Under Section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), it is unlawful to introduce or deliver for introduction into interstate commerce any new drug unless an approved New Drug Application (NDA) is in effect. Because clinical trials typically require shipping an unapproved, investigational drug across state lines to various clinical sites, sponsors must obtain a legal exemption from this prohibition. This exemption is secured by submitting an Investigational New Drug (IND) application under 21 CFR Part 312.

The primary purpose of an IND is to obtain a legal exemption from the interstate commerce ban, allowing the sponsor to ship the unapproved drug to clinical investigators in different states. Additionally, the IND serves as the regulatory gateway through which preclinical laboratory and animal safety data are translated into clinical investigations involving human subjects. The IND provides a comprehensive framework for the FDA to review the safety profile of the investigational drug, the scientific validity of the clinical protocols, and the adequacy of human subject protections.

There are two primary categories of INDs based on their commercial intent:

1. Commercial INDs: Submitted by pharmaceutical or biotechnology companies to gather the safety and efficacy data necessary to support a New Drug Application (NDA) for marketing approval.
2. Non-Commercial INDs (Investigator INDs): Submitted by individual physicians or academic researchers (sponsor-investigators) to study an unapproved drug, or an approved drug for a new indication, new patient population, or different dosage. These are also referred to as research INDs.

Other specialized IND types include Emergency INDs, which authorize the immediate use of an investigational drug in an emergency situation for a single patient who does not meet the criteria of an existing study protocol, and Treatment INDs, which provide access to promising investigational drugs for patients with serious or immediately life-threatening conditions before marketing approval is finalized.

---

Essential IND Forms: Form FDA 1571 and Form FDA 1572

The administration of an active IND requires the execution of specific regulatory forms that define the responsibilities of sponsors and investigators. The two most critical documents are Form FDA 1571 and Form FDA 1572.

Form FDA 1571: The IND Cover Sheet

Form FDA 1571 is the Investigational New Drug Application cover sheet. It serves as the official administrative contract between the sponsor and the FDA. Every initial IND submission, protocol amendment, safety report, information amendment, or annual report must be accompanied by this form. By signing Form FDA 1571, the sponsor provides a legally binding commitment to:

• Maintain control over the investigational drug and ensure it is only shipped to qualified investigators listed in the IND.
• Monitor the clinical investigations to ensure compliance with the protocol and Good Clinical Practice (GCP) guidelines.
• Screen and report adverse experiences in accordance with regulatory timelines.
• Submit annual progress reports and notify the FDA and investigators if the investigation is discontinued.

Key fields on Form FDA 1571 include the sponsor's contact information, the name of the investigational drug, the phase of the investigation (Phase 1, 2, 3, or 4), a list of the contents of the submission, and the signature of the sponsor's authorized representative.

Form FDA 1572: The Statement of Investigator

Form FDA 1572 is the Statement of Investigator. This document is completed and signed by the principal investigator (PI) at each clinical trial site. It represents a direct commitment from the investigator to the sponsor and the FDA. The PI's signature on the 1572 is a pledge to adhere to federal regulations and clinical protocols. Specifically, the investigator commits to:

• Conduct and supervise the study personally.
• Ensure that all associates, colleagues, and sub-investigators assisting in the study are informed of their obligations.
• Obtain informed consent from all human subjects in accordance with 21 CFR Part 50 and ensure Institutional Review Board (IRB) review under 21 CFR Part 56.
• Report adverse experiences to the sponsor in a timely manner.
• Maintain adequate and accurate records (case histories) and make them available for inspection by the FDA.

Key sections of Form FDA 1572 include:

1. Name and address of the investigator.
2. The investigator's curriculum vitae (CV) or statement of qualifications.
3. The names and addresses of clinical facilities where the study will be conducted.
4. The names and addresses of any clinical laboratories used for study-related testing.
5. The name and address of the reviewing IRB.
6. The names of sub-investigators (e.g., co-investigators, research coordinators, pharmacists) who make significant clinical contributions to the study.
7. The title and protocol number of the clinical trial.

---

The Lifecycle of Drug Development: IND Phases 1, 2, 3, and 4

The clinical investigation of a new drug under an IND is structured into four sequential phases, each designed to answer specific questions about the drug's safety, dosage, and efficacy.

Phase 1: Human Pharmacology

Phase 1 trials represent the first time an investigational drug is administered to humans. The primary focus is safety. Researchers evaluate how the drug is absorbed, distributed, metabolized, and excreted (pharmacokinetics), as well as its pharmacological actions (pharmacodynamics). These studies establish the maximum tolerated dose (MTD) and identify common side effects. While healthy volunteers are typically used, patients with the target disease may be enrolled if the drug is known to be highly toxic (e.g., cytotoxic chemotherapies).

Phase 2: Therapeutic Exploratory

Phase 2 trials are designed to evaluate the drug's preliminary efficacy in patients with the target disease or condition. Safety continues to be monitored closely, and researchers gather detailed data on short-term adverse effects. A critical goal of Phase 2 is to determine the optimal dosage regimen (dose-response relationship) to carry forward into larger trials.

Phase 3: Therapeutic Confirmatory

Phase 3 trials are large-scale, multi-center, randomized, controlled studies. Their primary objective is to confirm the preliminary evidence of efficacy gathered in Phase 2 and build a robust safety profile. These studies compare the investigational drug against the current standard of care, a placebo, or both. The data generated in Phase 3 provide the primary basis for the FDA's benefit-risk assessment during the review of a New Drug Application (NDA).

Phase 4: Therapeutic Use

Phase 4 trials, also known as post-marketing studies, are conducted after the FDA has approved the drug for commercial sale. These studies monitor the drug's performance in the general population under real-world clinical conditions. They are crucial for detecting rare, long-term side effects that may not have been observed in the smaller, highly controlled environment of pre-approval trials. Phase 4 studies may also explore new patient populations, pediatric applications, or interactions with other drugs.

---

The FDA Review Process: The 30-Day Safety Review Clock

Upon receiving an initial IND application, the FDA initiates a strict 30-day safety review clock. During this 30-calendar-day period, the sponsor is prohibited from shipping the investigational drug or starting any clinical trials. The FDA utilizes this window to review the IND to ensure that clinical subjects will not be exposed to unreasonable and significant risk of illness or injury.

The IND review is conducted by a multidisciplinary team within the FDA, typically consisting of a medical officer (physician), a pharmacologist/toxicologist, a chemist (reviewing the chemistry, manufacturing, and controls, or CMC), and a statistician.

The IND goes into effect (becomes active) exactly 30 calendar days after the FDA receives the application, unless the FDA notifies the sponsor of a clinical hold before the clock expires. If the 30 days pass with no communication from the FDA, the sponsor may legally proceed with the study on Day 31. However, in practice, sponsors usually wait for an official letter or communication confirming that the IND is active.

Clinical Hold (21 CFR 312.42)

A clinical hold is an official order issued by the FDA to delay a proposed clinical investigation or suspend an ongoing one. If a clinical hold is issued, the sponsor cannot administer the investigational drug to any subjects.

• Grounds for a Phase 1 clinical hold: The FDA can impose a hold if it finds that human subjects would be exposed to an unreasonable and significant risk, the clinical investigators are not qualified, the investigator brochure is misleading or incomplete, or the sponsor has submitted insufficient information to assess safety.
• Grounds for a Phase 2 or 3 clinical hold: In addition to the Phase 1 grounds, the FDA can impose a hold if the study protocol is clearly deficient in design to meet its stated objectives.

To resolve a clinical hold, the sponsor must address all deficiency issues identified by the FDA in writing. The FDA then has 30 days from the receipt of the sponsor's response to review the new information and decide whether to lift the hold.

---

IND Amendments and Safety Reporting Timelines

An active IND is a dynamic document. As the drug development program progresses, the sponsor must submit various updates and safety alerts to the FDA.

Types of IND Amendments

• Protocol Amendments (21 CFR 312.30): Required when there is a new study protocol, a change in an existing protocol (e.g., changes in inclusion/exclusion criteria, dosage, study duration, or safety monitoring that significantly affect subject safety), or when a new clinical investigator is added to the study.
• Information Amendments (21 CFR 312.31): Used to submit essential information that does not involve a protocol change, such as new chemistry/manufacturing data, toxicology results from ongoing animal studies, or clinical trial progress updates.
• Annual Reports (21 CFR 312.33): Sponsors must submit a progress report within 60 days of the anniversary of the date the IND went into effect. The report must summarize the progress of the investigations, safety data, and the planned clinical program for the coming year.

Safety Reports (21 CFR 312.32)

Sponsors must notify the FDA and all participating investigators of potential serious risks associated with the drug. These are submitted as IND Safety Reports.

• Definitional Criteria for Expedited Reporting: The event must be a serious, unexpected, suspected adverse reaction (SUSAR).
  • Serious: Results in death, a life-threatening adverse experience, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect.
  • Unexpected: Not listed in the current Investigator's Brochure (IB) or not listed at the specificity or severity observed.
  • Suspected Adverse Reaction: There is a reasonable possibility that the drug caused the adverse event.

Safety Reporting Timelines

1. 7-Day Safety Report (Fatal or Life-Threatening): The sponsor must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction as soon as possible, but no later than 7 calendar days after the sponsor's initial receipt of the information. This notification can be made via telephone, fax, or electronic submission. A written follow-up report must be submitted within 8 additional calendar days.
2. 15-Day Safety Report (Serious and Unexpected): The sponsor must notify the FDA and all participating investigators in writing of any serious, unexpected suspected adverse reaction (that is not fatal or life-threatening), or any clinically important finding from in vitro or animal testing suggesting significant risk, no later than 15 calendar days after the sponsor determines the event meets the reporting criteria.